{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:14:19Z","timestamp":1770488059874,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40272-016-0208-y","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T08:09:33Z","timestamp":1482998973000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["DTaP5-HB-IPV-Hib Vaccine (Vaxelis\u00ae): A Review of its Use in Primary and Booster Vaccination"],"prefix":"10.1007","volume":"19","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,29]]},"reference":[{"key":"208_CR1","unstructured":"European Centre for Disease Prevention and Control. Vaccine schedule. 2016. http:\/\/www.ecdc.europa.eu . Accessed 3 Jun 2016."},{"key":"208_CR2","unstructured":"European Centre for Disease Prevention and Control. Rapid risk assessment: shortage of acellular pertussis-containing vaccines and impact on immunisation programmes in the EU\/EEA. 2015. http:\/\/www.ecdc.europa.eu . Accessed 3 Jun 2016."},{"key":"208_CR3","unstructured":"European Centre for Disease Prevention and Control. ECDC guidance: scientific panel on childhood immunisation schedule: diphtheria-tetanus-pertussis (DTP) vaccination. 2009. http:\/\/www.ecdc.europa.eu . Accessed 3 Jun 2016."},{"issue":"1","key":"208_CR4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0974-777X.77298","volume":"3","author":"DA Skibinski","year":"2011","unstructured":"Skibinski DA, Baudner BC, Singh M, et al. Combination vaccines. J Global Infect Dis. 2011;3(1):63\u201372.","journal-title":"J Global Infect Dis"},{"key":"208_CR5","unstructured":"Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR. 1999;48(RR-5):1\u201315."},{"issue":"8","key":"208_CR6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/11204830-000000000-00000","volume":"70","author":"S Dhillon","year":"2010","unstructured":"Dhillon S. DTPa-HBV-IPV\/Hib Vaccine (Infanrix hexa\u2122): a review of its use as primary and booster vaccination. Drugs. 2010;70(8):1021\u201358.","journal-title":"Drugs"},{"issue":"1","key":"208_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","volume":"15","author":"PL McCormack","year":"2013","unstructured":"McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15(1):59\u201370.","journal-title":"Paediatr Drugs."},{"key":"208_CR8","unstructured":"European Medicines Agency. Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed) [Vaxelis\u00ae]: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 6 Sep 2016."},{"key":"208_CR9","unstructured":"European Medicines Agency. Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) [Vaxelis\u00ae]: assessment report. 2015. http:\/\/www.ema.europa.eu . Accessed 3 Jun 2016."},{"key":"208_CR10","unstructured":"European Medicines Agency. Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed) [Hexaxim\u00ae]: summary of product characteristics. 2012. http:\/\/www.ema.europa.eu . Accessed 3 Aug 2016."},{"issue":"6","key":"208_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4161\/hv.1.6.2377","volume":"1","author":"SA Halperin","year":"2005","unstructured":"Halperin SA, Langley JM, Hesley TM, et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum Vaccin. 2005;1(6):245\u201350.","journal-title":"Hum Vaccin"},{"issue":"19","key":"208_CR12","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.vaccine.2008.11.115","volume":"27","author":"SA Halperin","year":"2009","unstructured":"Halperin SA, Tapiero B, Diaz-Mitoma F, et al. Safety and immunogenicity of a hexavalent diphtheria\u2013tetanus\u2013acellular pertussis\u2013inactivated poliovirus\u2013Haemophilus influenzae b conjugate\u2013hepatitis B vaccine at 2, 3, 4, and 12\u201314 months of age. Vaccine. 2009;27(19):2540\u20137.","journal-title":"Vaccine"},{"issue":"6","key":"208_CR13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.vaccine.2010.11.053","volume":"29","author":"F Diaz-Mitoma","year":"2011","unstructured":"Diaz-Mitoma F, Halperin SA, Tapiero B, et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12\u201314 months of age. Vaccine. 2011;29(6):1324\u201331.","journal-title":"Vaccine"},{"issue":"1","key":"208_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/INF.0b013e3182717edf","volume":"32","author":"B Tapiero","year":"2013","unstructured":"Tapiero B, Halperin SA, Dionne M, et al. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Pediatr Infect Dis J. 2013;32(1):54\u201361.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"208_CR15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.inf.0000437806.76221.20","volume":"33","author":"SA Halperin","year":"2014","unstructured":"Halperin SA, Tapiero B, Dionne M, et al. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014;33(1):73\u201380.","journal-title":"Pediatr Infect Dis J"},{"key":"208_CR16","unstructured":"Vesikari T, Becker T, Vertruyen AF, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 3, 4, and 12 months. Pediatr Infect Dis J. 2016 (in press)."},{"issue":"33","key":"208_CR17","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","volume":"34","author":"SA Silfverdal","year":"2016","unstructured":"Silfverdal SA, Icardi G, Vesikari T, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months. Vaccine. 2016;34(33):3810\u20136.","journal-title":"Vaccine."},{"issue":"2","key":"208_CR18","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1542\/peds.2014-4102","volume":"136","author":"GS Marshall","year":"2015","unstructured":"Marshall GS, Adams GL, Leonardi ML, et al. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics. 2015;136(2):e323\u201332.","journal-title":"Pediatrics"},{"key":"208_CR19","doi-asserted-by":"crossref","unstructured":"Block SL, Klein NP, Sarpong K, et al. Lot-to-lot consistency, safety, tolerability, and immunogenicity of an investigational hexavalent vaccine in US infants. Pediatr Infect Dis J. 2016 (in press).","DOI":"10.1097\/INF.0000000000001405"},{"key":"208_CR20","unstructured":"US National Institutes of Health. ClinicalTrials.gov (NCT01337167). 2011. https:\/\/clinicaltrials.gov . Accessed 11 May 2016."},{"key":"208_CR21","unstructured":"US National Institutes of Health. ClinicalTrials.gov (NCT01340937). 2011. https:\/\/clinicaltrials.gov . Accessed 11 May 2016."},{"key":"208_CR22","unstructured":"Oliver JL, Snape MD, Heath PT, et al. Investigational hexavalent vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during primary series [abstract no. ESPID-0936]. In: 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 2015."},{"key":"208_CR23","doi-asserted-by":"crossref","unstructured":"Block SL, Marshall GS, Petrecz M, et al. Immunogenicity and safety of an investigational hexavalent vaccine against diphtheria, tetanus, pertussis (DTaP5), polio (IPV), H. Influenzae type b (Hib; PRP-OMPC), and hepatitis B (HepB) administered concomitantly with RV5 and PCV-13 in US Infants [slides]. In: American Academy of Pediatrics (AAP) National Conference & Exhibition. 2015.","DOI":"10.1542\/peds.137.Supplement_3.188A"},{"key":"208_CR24","doi-asserted-by":"crossref","unstructured":"Haverkate M, D\u2019Ancona F, Giambi C, et al. Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Euro Surveill. 2012;17(22):pii: 20183.","DOI":"10.2807\/ese.17.22.20183-en"},{"issue":"32","key":"208_CR25","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2015.06.030","volume":"33","author":"I Coster De","year":"2015","unstructured":"De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines: a time and motion study. Vaccine. 2015;33(32):3976\u201382.","journal-title":"Vaccine"},{"key":"208_CR26","unstructured":"GlaxoSmithKline Inc. Infanrix hexa\u00ae: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 3 Jun 2016."},{"key":"208_CR27","unstructured":"Sanofi Pasteur. Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine [Pentacel\u00ae]: US prescribing information. 2014. http:\/\/www.fda.gov . Accessed 6 Sep 2016."},{"key":"208_CR28","unstructured":"Sanofi Pasteur. Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Daptacel\u00ae): US prescribing information. 2002. http:\/\/www.fda.gov . Accessed 6 Sep 2016."},{"key":"208_CR29","unstructured":"Merck Sharp & Dohme Corp. Hepatitis B vaccine (recombinant) [Recombivax HB\u00ae]: US prescribing information. 1983. http:\/\/www.fda.gov . Accessed 6 Sep 2016."},{"key":"208_CR30","unstructured":"Merck Sharp & Dohme Corp. Liquid haemophilus b conjugate vaccine (meningococcal protein conjugate) [PedvaxHIB\u00ae]: US prescribing information. 2010. http:\/\/www.fda.gov . Accessed 6 Sep 2016."},{"key":"208_CR31","unstructured":"Sanofi Pasteur. Haemophilus b conjugate vaccine (tetanus toxoid conjugate) [ActHIB\u00ae]: US prescribing information. 1993. http:\/\/www.fda.gov . Accessed 6 Sep 2016."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0208-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-016-0208-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-016-0208-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T21:59:08Z","timestamp":1568671148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-016-0208-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1007\/s40272-016-0208-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]}}}